Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 19/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868322 | 0.89 | RYR2 (0.60) | RYR2KCNH2ATP2A2 | |
| SCHEMBL6867282 | 0.88 | RYR2 (0.60) | RYR2KCNH2 | |
| SCHEMBL15342811 | 0.86 | RYR2 (0.53) | RYR2KCNH2ATP2A2 | |
| Surlorian SCHEMBL29728244 | 0.86 | RYR2 (0.58) | RYR2KCNH2 | |
| Surlorian SCHEMBL15326996 | 0.86 | RYR2 (0.58) | RYR2KCNH2 | |
| SCHEMBL15327056 | 0.85 | RYR2 (0.56) | RYR2KCNH2 | |
| SCHEMBL15342814 | 0.85 | RYR2 (0.54) | RYR2KCNH2ATP2A2 | |
| SCHEMBL15327766 | 0.85 | RYR2 (0.54) | RYR2KCNH2ATP2A2 | |
| SCHEMBL15342810 | 0.85 | RYR2 (0.55) | RYR2KCNH2 | |
| Surlorian SCHEMBL29688989 | 0.82 | RYR2 (0.53) | RYR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-09-28 | — | — | US | disclosed |
| US-20140378437-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140378437-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8853198-B2 | Agents for treating disorders involving modulation of ryanodine receptors | LES LABORATOIRES SERVIER (FR) | 2014-10-07 | — | — | US | disclosed |
| US-8853198-B2 | Agents for treating disorders involving modulation of ryanodine receptors | LES LABORATOIRES SERVIER (FR) | 2014-10-07 | — | — | US | disclosed |
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140088171-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2708535-A1 | Agents for treating disorders involving modulation of ryanodine receptors | Les Laboratoires Servier (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-20130281512-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281512-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 165/4885ATP2A2 8/4885 |
| US-20230302013-A1 | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS | RYR2, RYR1, CACNB1 | RYR2 1/4885KCNH2 293/4885ATP2A2 7/4885 |
| US-20140378437-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 233/4885ATP2A2 5/4885 |
| US-20140088171-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 233/4885ATP2A2 5/4885 |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | RYR2 1/4885KCNH2 420/4885ATP2A2 3/4885 |
| US-20130281512-A1 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 233/4885ATP2A2 5/4885 |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885KCNH2 215/4885ATP2A2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.